Navigation Links
Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

Data from the mechanistic study being presented at the EASD meeting demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  For more information on this program or to download a copy of the presentation from the EASD meeting, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
2. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
3. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
4. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
5. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
6. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
7. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
8. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
9. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
11. Lexicon to Provide First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed surgical ... of Saint Luke’s Health System . Dr. Upadhyaya has served in the role ... joins Stanley P. Fisher, M.D., who has served as medical co-director of ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... in Oakland, California effectively destroyed the construction site and threatened numerous homes and ... July 7th article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly ... for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... long term skin conditions, including cancer. In the short term, overexposure to ...
(Date:7/24/2017)... ... July 24, 2017 , ... The ... Harbor, MD. This year's theme focuses on the new ISO/IEC 17025 standards. This ... and integrity in testing and calibration will be changed. , As an ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... Tuesday received the prestigious StorErotica “Consumer’s Choice” Award, for favorite sex toy. Created ... the 11th annual StorErotica Awards to be consumer voted. The Magic Wand Rechargeable ...
Breaking Medicine News(10 mins):